These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 21094269)
1. PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Stano A; van der Vlies AJ; Martino MM; Swartz MA; Hubbell JA; Simeoni E Vaccine; 2011 Jan; 29(4):804-12. PubMed ID: 21094269 [TBL] [Abstract][Full Text] [Related]
2. Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization. Stano A; Nembrini C; Swartz MA; Hubbell JA; Simeoni E Vaccine; 2012 Dec; 30(52):7541-6. PubMed ID: 23103199 [TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with poly(γ-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. Matsuo K; Koizumi H; Akashi M; Nakagawa S; Fujita T; Yamamoto A; Okada N J Control Release; 2011 Jun; 152(2):310-6. PubMed ID: 21402114 [TBL] [Abstract][Full Text] [Related]
4. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Ballester M; Nembrini C; Dhar N; de Titta A; de Piano C; Pasquier M; Simeoni E; van der Vlies AJ; McKinney JD; Hubbell JA; Swartz MA Vaccine; 2011 Sep; 29(40):6959-66. PubMed ID: 21787826 [TBL] [Abstract][Full Text] [Related]
5. Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles. Stano A; Scott EA; Dane KY; Swartz MA; Hubbell JA Biomaterials; 2013 Jun; 34(17):4339-46. PubMed ID: 23478034 [TBL] [Abstract][Full Text] [Related]
6. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. Klavinskis LS; Barnfield C; Gao L; Parker S J Immunol; 1999 Jan; 162(1):254-62. PubMed ID: 9886393 [TBL] [Abstract][Full Text] [Related]
7. Polymer nanomicelles for efficient mucus delivery and antigen-specific high mucosal immunity. Noh YW; Hong JH; Shim SM; Park HS; Bae HH; Ryu EK; Hwang JH; Lee CH; Cho SH; Sung MH; Poo H; Lim YT Angew Chem Int Ed Engl; 2013 Jul; 52(30):7684-9. PubMed ID: 23765547 [TBL] [Abstract][Full Text] [Related]
9. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Patel GB; Zhou H; Ponce A; Chen W Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279 [TBL] [Abstract][Full Text] [Related]
10. Mucosal inoculation of Lactobacillus expressing hCGbeta induces an anti-hCGbeta antibody response in mice of different strains. Yao XY; Yuan MM; Li DJ Methods; 2006 Feb; 38(2):124-32. PubMed ID: 16414267 [TBL] [Abstract][Full Text] [Related]
11. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Liu XS; Abdul-Jabbar I; Qi YM; Frazer IH; Zhou J Virology; 1998 Dec; 252(1):39-45. PubMed ID: 9875315 [TBL] [Abstract][Full Text] [Related]
12. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251 [TBL] [Abstract][Full Text] [Related]
13. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Slütter B; Bal S; Keijzer C; Mallants R; Hagenaars N; Que I; Kaijzel E; van Eden W; Augustijns P; Löwik C; Bouwstra J; Broere F; Jiskoot W Vaccine; 2010 Aug; 28(38):6282-91. PubMed ID: 20638455 [TBL] [Abstract][Full Text] [Related]
14. Mucosal vaccination using claudin-4-targeting. Kakutani H; Kondoh M; Fukasaka M; Suzuki H; Hamakubo T; Yagi K Biomaterials; 2010 Jul; 31(20):5463-71. PubMed ID: 20398936 [TBL] [Abstract][Full Text] [Related]
15. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. VanCott TC; Kaminski RW; Mascola JR; Kalyanaraman VS; Wassef NM; Alving CR; Ulrich JT; Lowell GH; Birx DL J Immunol; 1998 Feb; 160(4):2000-12. PubMed ID: 9469464 [TBL] [Abstract][Full Text] [Related]
16. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356 [TBL] [Abstract][Full Text] [Related]
17. Nanoparticles built by self-assembly of amphiphilic gamma-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Yoshikawa T; Okada N; Oda A; Matsuo K; Matsuo K; Kayamuro H; Ishii Y; Yoshinaga T; Akagi T; Akashi M; Nakagawa S Vaccine; 2008 Mar; 26(10):1303-13. PubMed ID: 18255205 [TBL] [Abstract][Full Text] [Related]
19. Lymphotactin acts as an innate mucosal adjuvant. Lillard JW; Boyaka PN; Hedrick JA; Zlotnik A; McGhee JR J Immunol; 1999 Feb; 162(4):1959-65. PubMed ID: 9973465 [TBL] [Abstract][Full Text] [Related]
20. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. Kim SH; Seo KW; Kim J; Lee KY; Jang YS J Immunol; 2010 Nov; 185(10):5787-95. PubMed ID: 20952686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]